TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06233331
Drug: Dose Level 3 ACU-D1 ointment
Normalized name: PHOSPHOLIPASE D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.
Study: NCT06477536
Drug: HB0034
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg, i.v. Q4W
Study: NCT04233190
Drug: Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: one inhalation, twice daily
Study: NCT03868943
Drug: Soliramfetol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
Study: NCT06564038
Drug: AZD0486
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).
Study: NCT06564038
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as IV infusion as per standard of care.
Study: NCT06564038
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered as IV infusion as per standard of care.
Study: NCT06208306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
Study: NCT05936359
Drug: INCA033989
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCA033989 will be administered at protocol defined dose.
Study: NCT05913752
Drug: CMND-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class
Study: NCT05251259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised participants will receive matching placebo to Atuliflapon.
Study: NCT06425900
Drug: Winlevi (Clascoterone) cream 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed twice daily (BID)
Study: NCT06087406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride administered intravenously
Study: NCT04789070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05935085
Drug: ANB032
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTLA agonist antibody
Study: NCT05935085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05185583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.
Study: NCT06486051
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2/day IV for three consecutive days
Study: NCT04728711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
Study: NCT04279847
Drug: INCB057643
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB057643 dose escalation and dose expansion.
Study: NCT05606341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline injection supplied by the NYU Investigational Pharmacy.
Study: NCT06506422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg Placebo daily for 12 weeks
Study: NCT05636618
Drug: [212Pb]VMT-α-NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered every 8 weeks for a maximum of four doses
Study: NCT05636618
Drug: [212Pb]VMT-α-NET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered at the RPh2D and schedule determined in Phase I dose escalation
Study: NCT05259839
Drug: Etentamig
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT05819619
Drug: Prophylactic use of ibuprofen and ondansetron post misoprostol administration
Normalized name: naproxen and misoprostol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic use of ibuprofen and ondansetron post misoprostol administration
Study: NCT05819619
Drug: Use of ibuprofen and ondansetron at symptom onset post misoprostol administration
Normalized name: naproxen and misoprostol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
Study: NCT05588843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT05305547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a round tablet.
Study: NCT06136650
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally or IM as a rescue drug
Study: NCT05411484
Drug: NanoDOX® Hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
Study: NCT05071430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB-1 matched placebo
Study: NCT06474598
Drug: MTX228
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolimidone was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, tolimidone has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as Tolimidone, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabete
Study: NCT02492074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of placebo
Study: NCT04721548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of solution twice a day.
Study: NCT04240626
Drug: Dilaudid Injectable Product
Normalized name: Dilaudid Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: .5-1 mg IV Q3 hours and IV Tylenol 1000mg every 6 hours post surgery transitioning to oral pain control medications (Hycet 7.5/325mg/5 ml, 5-10 ml every 4 hours
Study: NCT04240626
Drug: Marcaine Injectable Product
Normalized name: Marcaine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% local injectable anesthetic agent infiltrated at all laparoscopic incision sites for both groups.
Study: NCT04240626
Drug: Hycet 7.5Mg-325Mg/15Ml Solution
Normalized name: Hycet 7.5mg-325mg/15ml Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 10-15ml q4h prn for pain control
Study: NCT04240626
Drug: Flexeril Oral Product
Normalized name: Flexeril Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg orally q8h prn for muscle spasms.
Study: NCT05885737
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Study: NCT05706129
Drug: [68Ga]Ga-DPI-4452
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[68Ga\]Ga-DPI-4452, administered as IV injection.
Study: NCT05608291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
Study: NCT04693351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
Study: NCT05859750
Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h
Study: NCT05859750
Drug: Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin, 85 mg/m²; irinotecan, 180 mg/m²; leucovorin, 400 mg/m²; and fluorouracil, 400 mg/m² given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks
Study: NCT05501288
Drug: Huashi Baidu granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.
Study: NCT06507839
Drug: THRV-1268
Approvals — FDA: no, EMA: no, PMDA: no
Description: THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
Study: NCT05735366
Drug: SAIL66
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAIL66 as a IV infusion
Study: NCT06161571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by SC injection
Study: NCT06371534
Drug: QL2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection 3-5 min D1 (Day 1, single dose)
Study: NCT06371534
Drug: DARZALEX FASPRO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection 3-5 min D1 (Day 1, single dose)
Study: NCT05179499
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
Study: NCT05042973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matches the active drug in appearance, odor and labelling.
Study: NCT06529419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered by inhalation
Study: NCT06299462
Drug: ATG 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG 2.5 mg/kg on days -3 and -2
Study: NCT06299462
Drug: Cyclophosphamide injection
Normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 50 mg/kg on days +3 and +4
Study: NCT06299462
Drug: ATG 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG 2.5 mg/kg on day -2 + 1.5 mg/kg on day -3
Study: NCT06238466
Drug: AZD1705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.
Study: NCT06389110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution.
Study: NCT04620681
Drug: Standard of Care Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care cytarabine-based chemotherapy
Study: NCT06280196
Drug: BAT3306
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vial of 4 mL of concentrate contains 100 mg of BAT3306
Study: NCT06280196
Drug: EU-Keytruda®
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
Study: NCT06280196
Drug: US-Keytruda®
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vial of 4 mL of concentrate contains 100 mg of pembrolizumab
Study: NCT05747534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
Study: NCT05241873
Drug: BLU-451
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
Study: NCT06197217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
Study: NCT05228184
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
Study: NCT05088421
Drug: BWC0977
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
Study: NCT05088421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Study: NCT06675565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered SC
Study: NCT05681260
Drug: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
Study: NCT05681260
Drug: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
Study: NCT05681260
Drug: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
Study: NCT06147921
Drug: Verasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by sinonasal irrigation.
Study: NCT03862430
Drug: NanO2TM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL/kg NanO2 infusion
Study: NCT03862430
Drug: Placebo Saline Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Infusion
Study: NCT04172532
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06544291
Drug: Placebo 0mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.
Study: NCT05102006
Drug: LBL-007 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBL-007 Injection; dose A or dose B; Q3W
Study: NCT06202079
Drug: GZR4 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GZR4 injection s.c., once-weekly, treat-to-target dose
Study: NCT05447286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
Study: NCT05723107
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
Study: NCT06532136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo orally once daily.
Study: NCT05036291
Drug: NB004 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA .
Study: NCT05534984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Oral capsules~* Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days
Study: NCT04586660
Drug: XGEVA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15.
Study: NCT06372496
Drug: Inhaled corticosteroids/long-acting beta-2 agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ICS/LABA
Study: NCT06000410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
Study: NCT05776953
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Ketorolac for pain
Study: NCT05131022
Drug: NX-5948
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NX-5948
Study: NCT06444815
Drug: VET3-TGI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oncolytic vaccinia virus engineered with immunomodulatory transgenes
Study: NCT04091295
Drug: DNG64
Normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'DNG64'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of DNG64 for treatment of advanced pancreatic cancer, sarcoma and carcinoma of breast
Study: NCT04148742
Drug: DZD9008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
Study: NCT05463263
Drug: STP938
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule
Study: NCT05374785
Drug: CPL409116
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPL409116 contained in the tablet called PG242 (60 mg)
Study: NCT05643534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive matching placebo
Study: NCT06440967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT06440967
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02632994
Drug: LY2503029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT02632994
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05328752
Drug: XXB750
Approvals — FDA: no, EMA: no, PMDA: no
Description: XXB750
Study: NCT05328752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05108558
Drug: Control - Crossover to CCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
Study: NCT06084416
Drug: Sovilnesib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovilnesib tablets will be given orally.
Study: NCT04956640
Drug: LY3537982
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06006117
Drug: - Rituximab + Lenalidomide (28-days cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12
Study: NCT06448624
Drug: Placebo 3 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 days after CIED implantation
Study: NCT05735249
Drug: ARN-75039 oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: Up to 5 single escalating doses MAD: Up to 3 escalating doses Food-effect: Selected single dose
Study: NCT05735249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given at frequency and amounts matching ARN- 75039 dosing regimen
Study: NCT04986930
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
Study: NCT05720299
Drug: AKK Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of AKK placebo